We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimization for Regorafenib in HCC (ReDos HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04476329
Recruitment Status : Terminated (Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.)
First Posted : July 20, 2020
Last Update Posted : December 30, 2021
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
SC Liver Research Consortium, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 13, 2021
Actual Study Completion Date : December 10, 2021